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Electroconvulsive therapy: we are hesitant to
use the most effective treatment for severe
depression
There is little doubt that electroconvulsive therapy
(ECT) is the most effective treatment for severe
major depression. ECT is superior to other biologi-
cal treatments for severe depression, both in remis-
sion rate and in speed of remission. Despite its
superior efficacy, ECT is seriously underused. The
limited use of ECT is probably because of stigma
associated with the treatment, stereotypical negative
images in the media, concerns about adverse effects
and limited access. Also, in several guidelines, for
example the NICE guideline (1), ECT is positioned
at the very end of the treatment algorithm.
The review by Kellner et al. (2), which is pub-
lished in this issue, is a valuable addition to ECT
literature. This paper is very useful, since it is both
comprehensive and easy to read. It covers its cur-
rent use, common and uncommon indications for
ECT, predictors of outcome, but also technical
treatment parameters, adverse effects and mainte-
nance treatment. The central point of this review
is, however, its main indication, severe major
depression.
As stated in the review, many treatment guideli-
nes advise to ‘consider ECT in psychotic depres-
sion’. The question is as follows: are there
altogether reasonable arguments against ECT as
first-line treatment in psychotic depression?
ECT achieved response rates of up to 90% (3) in
patients with psychotic depression. These numbers
are way beyond the efficacy of treatment with
antidepressants in psychotic depression. The effi-
cacy of antidepressants in psychotic depression
varies between studies, a response rate of 50% to
treatment with imipramine (4) being the most
favourable result.
There is some evidence to support that the com-
bination of an antidepressant and an antidepres-
sant may be the superior pharmacotherapy for
psychotic depression (5). However, in the STOP-
PD study, combination treatment with olanzapine
and sertraline resulted in a remission rate of 30%
after 8 weeks and 42% after 12 weeks, which are
far below the efficacy of ECT.
With regard to the results of ECT in the longer
term, for example one year after the ECT course,
post-ECT relapse is a major cause for concern.
However, in an observational study by our group
(6), post-ECT relapse after 12 months appeared to
be remarkably low in the sample with psychotic
depression, 20%. In this sample, continuation
treatment was with a tricyclic antidepressant
(TCA) or a TCA-lithium combination. Appar-
ently, the favourable effect of ECT in psychotic
depression is sustained in the large majority of
patients: of 90% responders, 980% maintained
response = 72% of patients who received ECT
remaining well one-year post-ECT. In conclusion,
without any doubt ECT should be the treatment of
choice in patients with psychotic depression.
In mixed populations of older patients, consist-
ing of patients both with and without psychotic
features, high remission rates were reported as
well. In the MODECT study (7), the remission rate
amounted to 66% in patients treated with right
unilateral ECT. In the PROSPECT study (8), a
remission rate of 73% was found in another sam-
ple of older patients, who were treated with bitem-
poral ECT. Finally, in the PRIDE study (9), a
comparable remission rate was reported, also in a
sample of older patients, the large majority with-
out psychotic features, who were treated with right
unilateral ECT.
As mentioned above, there are considerable con-
cerns about the efficacy of ECT in the longer term,
especially for patients with non-psychotic depres-
sion. A meta-analysis (10) estimated, that even
with continuation pharmacotherapy or continua-
tion ECT, about 50% of the patients will relapse
within 12 months. However, combining continua-
tion pharmacotherapy and continuation ECT may
result in considerable lower relapse rates. Kellner
et al. (11) demonstrated this in a randomized con-
trolled trial in patients with geriatric depression. In
their study, a venlafaxine–lithium combination
plus a continuation ECT schedule (four continua-
tion ECT treatments followed by further ECT only
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as needed) resulted in a 13% relapse rate during
the 6 months after the index course.
A topic closely related to the efficacy of ECT in
major depression is the search for predictors of
ECT response. As discussed earlier, psychotic fea-
tures are an obvious predictor of ECT outcome
(12). Other positive predictors are age and psy-
chomotor symptoms. Melancholia has long been
considered to be a good clinical predictor of ECT
outcome in depression, but meta-analyses on the
predictive value of melancholic symptoms were
inconclusive because of study heterogeneity (12).
Although there is uncertainty about the predictive
value of melancholia, a recent study showed that
patients with CORE-defined melancholic depres-
sion had a five times greater chance of reaching
response than those with non-melancholic depres-
sion (13). Baseline severity is also considered as a
positive predictor of ECT outcome. This is proba-
bly correct, albeit that it seems impossible to disen-
tangle severity from psychotic symptoms or
melancholic subtype. Although the literature
regarding the influence of treatment resistance is
somewhat divided, a recent meta-analysis con-
cluded that treatment resistance is associated with
a reduced response to ECT. Still, the overall remis-
sion rate in patients with treatment-resistant
depression is rather encouraging, around 50%
(14). A longer duration of the index episode
reduces the efficacy of ECT, but it is strongly con-
founded with treatment resistance, so it is hard to
tell which of the two is the most relevant predictor.
Furthermore, ECT has a very fast antidepres-
sant effect, a significant improvement in depressive
symptomatology may be observed after two ECT
sessions (9). In a recent study with older depressed
patients, a substantial number of patients (24%)
that attained full remission did so within 4 ECT
sessions (15).
In choosing between ECT and antidepressants,
the fast antidepressant effect of ECT may be
equally valuable as its superior efficacy. A substan-
tial antidepressant effect within one week, which is
often seen during an ECT course, is unfeasible dur-
ing treatment with antidepressants. It often takes
four weeks of antidepressant treatment until an
obvious decrease in depression severity can be
observed. Even if patients are not actively suicidal,
do not show catatonic features and have an accept-
able food and fluid intake, waiting four weeks for
an antidepressant effect must be extremely long for
patients who feel hopeless and are convinced that
they have made terrible mistakes.
Hopefully, the review by Kellner et al. (2) can
reduce some of the hesitation felt by treating psy-
chiatrists and authors of guidelines. It could help
to reduce the negative influence of stigma by edu-
cating its readers. Actually, we suggest that psychi-
atrists who treat patients with mood disorders or
psychotic disorders as well as all residents in psy-
chiatry should read this paper. They are the ones
destined to integrate its recommendations into
their clinical practice. This review shows that ECT
should be first-line treatment in patients with psy-
chotic depression. Furthermore, ECT should be
considered as first-line treatment in patients with
severe melancholic depression (without psychotic
features).
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